Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided?

Clemens Warnke, Til Menge, Hans Peter Hartung, Michael K. Racke, Petra D. Cravens, Jeffrey L. Bennett, Elliot Frohman, Benjamin Greenberg, Scott S. Zamvil, Ralf Gold, Bernhard Hemmer, Bernd C. Kieseier, Olaf Stuve

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Natalizumab (Tysabri) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, 3 patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with progressive multifocal leukoencephalopathy (PML). The agent was later reapproved and its use restricted to monotherapy in patients with relapsing forms of MS. Since reapproval in 2006, additional cases of PML were reported in patients with MS receiving natalizumab monotherapy. Thus, there is currently no convincing evidence that natalizumab-associated PML is restricted to combination therapy with other disease-modifying or immunosuppressive agents. In addition, recent data indicate that risk of PML might increase beyond 24 months of treatment.

Original languageEnglish (US)
Pages (from-to)923-930
Number of pages8
JournalArchives of Neurology
Volume67
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Progressive Multifocal Leukoencephalopathy
Multiple Sclerosis
Immunosuppressive Agents
Therapeutics
Monoclonal Antibodies
Natalizumab
Causal
Therapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Natalizumab and progressive multifocal leukoencephalopathy : What are the causal factors and can it be avoided? / Warnke, Clemens; Menge, Til; Hartung, Hans Peter; Racke, Michael K.; Cravens, Petra D.; Bennett, Jeffrey L.; Frohman, Elliot; Greenberg, Benjamin; Zamvil, Scott S.; Gold, Ralf; Hemmer, Bernhard; Kieseier, Bernd C.; Stuve, Olaf.

In: Archives of Neurology, Vol. 67, No. 8, 08.2010, p. 923-930.

Research output: Contribution to journalArticle

Warnke, C, Menge, T, Hartung, HP, Racke, MK, Cravens, PD, Bennett, JL, Frohman, E, Greenberg, B, Zamvil, SS, Gold, R, Hemmer, B, Kieseier, BC & Stuve, O 2010, 'Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided?', Archives of Neurology, vol. 67, no. 8, pp. 923-930. https://doi.org/10.1001/archneurol.2010.161
Warnke, Clemens ; Menge, Til ; Hartung, Hans Peter ; Racke, Michael K. ; Cravens, Petra D. ; Bennett, Jeffrey L. ; Frohman, Elliot ; Greenberg, Benjamin ; Zamvil, Scott S. ; Gold, Ralf ; Hemmer, Bernhard ; Kieseier, Bernd C. ; Stuve, Olaf. / Natalizumab and progressive multifocal leukoencephalopathy : What are the causal factors and can it be avoided?. In: Archives of Neurology. 2010 ; Vol. 67, No. 8. pp. 923-930.
@article{08d7e02b29454e79a81ffafff7621c8e,
title = "Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided?",
abstract = "Natalizumab (Tysabri) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, 3 patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with progressive multifocal leukoencephalopathy (PML). The agent was later reapproved and its use restricted to monotherapy in patients with relapsing forms of MS. Since reapproval in 2006, additional cases of PML were reported in patients with MS receiving natalizumab monotherapy. Thus, there is currently no convincing evidence that natalizumab-associated PML is restricted to combination therapy with other disease-modifying or immunosuppressive agents. In addition, recent data indicate that risk of PML might increase beyond 24 months of treatment.",
author = "Clemens Warnke and Til Menge and Hartung, {Hans Peter} and Racke, {Michael K.} and Cravens, {Petra D.} and Bennett, {Jeffrey L.} and Elliot Frohman and Benjamin Greenberg and Zamvil, {Scott S.} and Ralf Gold and Bernhard Hemmer and Kieseier, {Bernd C.} and Olaf Stuve",
year = "2010",
month = "8",
doi = "10.1001/archneurol.2010.161",
language = "English (US)",
volume = "67",
pages = "923--930",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Natalizumab and progressive multifocal leukoencephalopathy

T2 - What are the causal factors and can it be avoided?

AU - Warnke, Clemens

AU - Menge, Til

AU - Hartung, Hans Peter

AU - Racke, Michael K.

AU - Cravens, Petra D.

AU - Bennett, Jeffrey L.

AU - Frohman, Elliot

AU - Greenberg, Benjamin

AU - Zamvil, Scott S.

AU - Gold, Ralf

AU - Hemmer, Bernhard

AU - Kieseier, Bernd C.

AU - Stuve, Olaf

PY - 2010/8

Y1 - 2010/8

N2 - Natalizumab (Tysabri) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, 3 patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with progressive multifocal leukoencephalopathy (PML). The agent was later reapproved and its use restricted to monotherapy in patients with relapsing forms of MS. Since reapproval in 2006, additional cases of PML were reported in patients with MS receiving natalizumab monotherapy. Thus, there is currently no convincing evidence that natalizumab-associated PML is restricted to combination therapy with other disease-modifying or immunosuppressive agents. In addition, recent data indicate that risk of PML might increase beyond 24 months of treatment.

AB - Natalizumab (Tysabri) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, 3 patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with progressive multifocal leukoencephalopathy (PML). The agent was later reapproved and its use restricted to monotherapy in patients with relapsing forms of MS. Since reapproval in 2006, additional cases of PML were reported in patients with MS receiving natalizumab monotherapy. Thus, there is currently no convincing evidence that natalizumab-associated PML is restricted to combination therapy with other disease-modifying or immunosuppressive agents. In addition, recent data indicate that risk of PML might increase beyond 24 months of treatment.

UR - http://www.scopus.com/inward/record.url?scp=77955031189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955031189&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2010.161

DO - 10.1001/archneurol.2010.161

M3 - Article

C2 - 20697042

AN - SCOPUS:77955031189

VL - 67

SP - 923

EP - 930

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 8

ER -